Results 21 to 30 of about 125,690 (294)

Time spent with cats is never wasted: Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring animal model of the human disease [PDF]

, 2018
BackgroundIn humans, acromegaly due to a pituitary somatotrophic adenoma is a recognized cause of increased left ventricular (LV) mass. Acromegalic cardiomyopathy is incompletely understood, and represents a major cause of morbidity and mortality.
A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Mestron, A Piovesan, AC Dirtu, AM Pereira, B Posch, BJ Maron, BPP Meij, BR Bond, C Paige, C-Y Liu, CJL Little, CR Lamb, David B. Church, David J. Connolly, DJ Connolly, F Fracassi, G Jacobs, G Lombardi, G Lombardi, J Dal, J Gilbert, JA Myers, JK Sangster, JM Fletcher, JR Payne, JT Lie, Kieran Borgeat, LJ Wilkie, Lois Wilkie, M Galderisi, M Lesser, M Maxie Grant, M Nishiki, M Rosca, M-LL Jaffrain-Rea, MD Kittleson, ME Peterson, ME Peterson, NJ Pereira, Norelene Harrington, NS Moise, NS Moise, O Kershaw, OM Dekkers, P Menaut, PR Fox, PR Fox, PR Fox, PR Fox, PR Fox, R Baldelli, R Gostelow, R Pivonello, RC Weichselbaum, S Brown, S Fazio, S Fazio, S Fazio, S Fieffe, S Murarka, S Niessen, SJM Niessen, SJM Niessen, SJM Niessen, SK Liu, SK Liu, Stijn J. M. Niessen, SV Keyte, T Wagner, T. Rosol, Vincenzo Lionetti, Virginia Luis Fuentes, WL McGuffin   +80 more
core   +2 more sources

Cardiac manifestations of PRKAG2 mutation. [PDF]

, 2018
BACKGROUND:The Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) cardiac syndrome is characterized by glycogen accumulation in the cardiac tissue.
Ardehali, Reza, Banankhah, Pooya, Dota, Anthony, Fishbein, Gregory A   +3 more
core   +1 more source

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

Scientific Reports, 2021
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM).
Styliani Vakrou, Yamin Liu, Li Zhu, Gabriela V. Greenland, Bahadir Simsek, Virginia B. Hebl, Yufan Guan, Kirubel Woldemichael, Conover C. Talbot, Miguel A. Aon, Ryuya Fukunaga, M. Roselle Abraham   +11 more
doaj   +1 more source

COVID-19 in Adults With Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Background: Individuals with cardiovascular disease are considered high risk for severe COVID-19. However, the clinical impact of COVID-19 in patients with hypertrophic cardiomyopathy (HCM) is unknown.
Milla E. Arabadjian, Maria C. Reuter, Alexandra Stepanovic, Mark V. Sherrid, Daniele Massera   +4 more
doaj   +1 more source

Feline Hypertrophic Cardiomyopathy: A Spontaneous Large Animal Model of Human HCM. [PDF]

, 2017
Hypertrophic cardiomyopathy (HCM) is a common disease in pet cats, affecting 10-15% of the pet cat population. The similarity to human HCM, the rapid progression of disease, and the defined and readily determined endpoints of feline HCM make it an ...
Freeman, Lisa M, Huggins, Gordon S, Maron, Martin S, Rush, John E, Stern, Joshua A   +4 more
core   +2 more sources

Weight loss in hypertrophic cardiomyopathy: A clinical case series

International Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Background: Obesity is prevalent among patients with hypertrophic cardiomyopathy (HCM). Obese HCM patients have greater wall thickness, LV mass, worse hemodynamic function and NYHA class. Weight loss may favorably influence the HCM phenotype.
Maria C. Reuter, Daniele Massera, Leon Axel, Larry A. Latson, Jonathan M. Goldstein, Alexandra Stepanovic, Mark V. Sherrid   +6 more
doaj   +1 more source

Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy [PDF]

, 2019
BackgroundPulmonary hypertension (PH) is a known complication of HCM and is a strong predictor of mortality. We aim to investigate the relationship between microvascular dysfunction measured by quantitative PET and PH in HCM patients.MethodsEighty-nine ...
Leal, Jeffrey P, Liu, Min, Pomper, Martin G, Tsui, Benjamin M. W., Wong, Dean F, Zhao, Min, Zhou, Yun   +6 more
core   +3 more sources

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

AIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren, Yongbing Wang, Rui Hu, Lei Zuo, Liwen Liu, Heng Zhao   +5 more
doaj   +1 more source

Non-compaction cardiomyopathy – brief review [PDF]

, 2017
Left ventricular non-compaction cardiomyopathy is a genetic disorder characterized by the presence of two myocardial layers with numerous prominent trabeculations and deep inter-trabecular recesses that communicate with the ventricular cavity.
Berceanu, Mihaela, Constantin, Anca, Donoiu, Ionuț, Istrătoaie, Octavian, Militaru, Constantin, Mirea, Oana, Mănescu, Mirela, Târtea, Georgică Costinel   +7 more
core   +3 more sources